| Ytd | 211.18% | |
| 1y | 570.84% |
| Open | 93.14 | Prev Close | 91.71 | Low | 92.31 | High | 96.00 | Mkt Cap | 3.53B |
| Vol | 585.51K | Avg Vol | 1.79M | EPS | -1.94 | P/E | -48.62 | Forward P/E | -34.83 |
| Beta | -0.35 | Short Ratio | 5.59 | Inst. Own | 92.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 73.16 | 200-d Avg | 46.21 | 1yr Est | 144.67 |
ORKA News
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains
Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the pric
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera
On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) wi
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analy
https://www.sec.gov/Archives/edgar/data/907654/000121390026049372/ea0288174-424b5_oruka.htm
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) wit
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the pric
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and ra
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on develo
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the
Oruka Therapeutics shares rise as ORKA-001 shows strong psoriasis clearance rates and durable dosing
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16Favorable safety profile consistent with the IL-2
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up
Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and rais
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and mainta
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) wit
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and mainta
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and ra
Guggenheim analyst Yatin Suneja maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises
$1,000,000,000 Common StockPreferred StockDepositary SharesWarrants From time to time, Oruka Therape
Leerink Partners analyst David Risinger maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperf
Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and ra
BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains
Stifel analyst Alex Thompson maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and mainta
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and mai
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.45) per share which beat the analy
